Nonsquamous non-small-cell lung cancer
Conditions
Interventions
Bevacizumab 15mg/kg d1 q3w until PD Pemetrexed 500mg/m2 d1 q3w until PD
Sponsors
Central Japan Lung Study Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Histologically or cytologicalliy confirmed Stage3/4 non-squamous non-small cell lung cance 2) Age years or or older 3) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 4) With one or more measurable disease based on Response Evaluation Criteria in Solid Tumors 5) Adequate organ function 6)A life expectancy of more than 3 months. 7)All patients provided written informed consent before initiation of study-related procedures.
Exclusion criteria
Exclusion criteria: 1) symptomatic brain metastasis 2) History of hemoptysis with 2.5mL or more 3) severe comorbidity (cardiovascular disease, pulmonary fibrosis/interstitial pneumonia, tendency to hemorrhages, uncontrolled hypertension or diabetes) 4) History of active double cancer within 5 years. 5) uncontrolled retention of fluid 6)receiving more than two anticoagulant drugs 7) active gastrointestinal bleeding or intraperitoneal inflammation 8) other inadequacy cases judged by attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety, Disease Control Rate (DCR), Response rate (RR), Overall Survival (OS), Quality of life (QOL), Exploration of biomarkers, Side effect prediction using the laboratory data | — |
Countries
Japan
Contacts
Public ContactEiji Kojima
Komaki City Hospital Division of Respiratory and Allergy Medicine
Outcome results
None listed